Clinical Trials Logo

Clinical Trial Summary

Patients with brain tumours experience a loss of independence, which may occur suddenly or gradually. Communication with the patient may be rapidly impaired, due to impaired alertness, language and/or neurocognitive disorders. In addition to these clinical symptoms, there is a high level of anxiety and depression in this population due to the severity of the diagnosis, with a major impact on the patients' quality of life. In this study, we are mainly interested in the proportion of this population with communication disorders where speech therapy is important In order to better take into account anxiety, which is often difficult to verbalise due to communication problems, sophrology can be proposed as an alternative to psychological support, which is often too complicated or inappropriate. After having noted positive feedback from patients after joint speech therapy and sophrology treatment, we wish to evaluate the interest of coupling sophrology treatment for patients with glial tumours requiring speech therapy. Our hypothesis is that this association would improve the level of anxiety, the quality of life and have a positive impact on the patient's speech therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05189366
Study type Interventional
Source Institut Cancerologie de l'Ouest
Contact CELINE THOMAS
Phone +33 240679900
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date February 2022
Completion date August 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Not yet recruiting NCT05139277 - Evaluation of the CONVIVO System N/A